Loading data for PTHS — first visit, this takes a few seconds.
Pelthos Therapeutics Inc.
19.42 -0.90 (-4.43%)
18.92 -2.57%
- Capitalización de mercado
- $74.35M
- Volumen
- 63.5K
- Próxima fecha de resultados
- Nov 12, 2026
Pelthos Therapeutics Inc. (PTHS): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $15.60M | n/a | n/a |
| EPS | -$3.79 | -$0.84 | +29.55% |
Métricas
- Precio de compra
- 7.84
- Ingresos (TTM)
- 43.3M
- Beneficio neto (TTM)
- -86.4M
- 3.05
- -27.36
- n/a
- -3.42
- P/B (TTM)
- -48.07
- P/S (TTM)
- 1.72
- Fecha de resultados
- Nov 12, 2026
- Precio de venta
- 24.83
- Volumen
- 63,518
- Volumen medio (20D)
- 59,766
- Abierto
- 20.29
- Anterior Cerrar
- 20.32
- Rango del día
- 18.20 - 21.00
- Rango de 52 semanas
- 18.19 - 37.50
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Pelthos Therapeutics Inc.
Ver perfil →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Industria Biotechnology
Sector Healthcare
IPO Fecha Feb 16, 2024
Empleados 92
Bolsa de Valores NYSE American
Símbolo bursátil PTHS
Sitio web https://pelthos.com